Interferon Beta-1a (AVONEX(®)) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study

por Kleinschnitz, Christoph, Niemczyk, Gabriele, Rehberg-Weber, Karin, Wernsdörfer, Colin
Publicado 2015

Adherence and cost in multiple sclerosis patients treated with IM IFN beta-1a: impact of the CARE patient management program

por Katsarava, Zaza, Ehlken, Birgit, Limmroth, Volker, Taipale, Kirsi, Patel, Sarita Noemi, Niemczyk, Gabriele, Rehberg-Weber, Karin, Wernsdörfer, Colin
Publicado 2015